Clinical Laserthermia Systems AB (FRA:LS60) Research & Development: €0.00 Mil (TTM As of Mar. 2026)


FRA:LS60 Clinical Laserthermia Systems AB FRA:LS60
36 GF Score
Price €0.27
GF Value €0.29
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Clinical Laserthermia Systems AB Research & Development?

Clinical Laserthermia Systems AB FRA:LS60 -2.91% 36 Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:LS60 with a GF Score™ of 36/100 and a GF Value™ of €0.29 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Clinical Laserthermia Systems AB's Research & Development for the three months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Clinical Laserthermia Systems AB  (FRA:LS60) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Clinical Laserthermia Systems AB Research & Development Related Terms

Clinical Laserthermia Systems AB Research & Development Historical Data

* Premium members only.

The historical data trend for Clinical Laserthermia Systems AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinical Laserthermia Systems AB Research & Development Chart

Clinical Laserthermia Systems AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Clinical Laserthermia Systems AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:LS60
36GF Score
Clinical Laserthermia Systems AB FRA:LS60
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinical Laserthermia Systems AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Clinical Laserthermia Systems AB (FRA:LS60) has a Research & Development of €0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Clinical Laserthermia Systems AB and its competitors.
Is Clinical Laserthermia Systems AB's Research & Development too high?
Clinical Laserthermia Systems AB's current Research & Development is €0.00 Mil. Overall, Clinical Laserthermia Systems AB has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Clinical Laserthermia Systems AB's Research & Development compare to ABT and SYK?
Clinical Laserthermia Systems AB's Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Clinical Laserthermia Systems AB and its competitors. Clinical Laserthermia Systems AB's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinical Laserthermia Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB (FRA:LS60) is currently considered Fairly Valued. The stock's GF Value™ is €0.29, compared to a current price of €0.27 — trading 7.9% below its estimated fair value. The current Research & Development is €0.00 Mil. Clinical Laserthermia Systems AB's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Clinical Laserthermia Systems AB (FRA:LS60), the current Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinical Laserthermia Systems AB (FRA:LS60) Overvalued in 2026?

Based on GuruFocus' analysis, Clinical Laserthermia Systems AB stock appears to be undervalued. The current stock price of €0.27 is trading 7.9% below its estimated GF Value™ of €0.29. GuruFocus considers Clinical Laserthermia Systems AB to be Fairly Valued.

Key valuation signals for FRA:LS60:

  • Research & Development: €0.00 Mil
  • GF Value™: €0.29 vs. price of €0.27 (7.9% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the FRA:LS60 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinical Laserthermia Systems AB Business Description

Other Exchanges CLS B:Sweden
Address Scheelevagen 2, Medicon village, Lund, SWE, 223 81
Clinical Laserthermia Systems AB develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe.
36GF Score

Get the complete analysis for FRA:LS60

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.29
GF Value